Tremfya patent?

What is the Tremfya patent situation?

Tremfya, also known as guselkumab, is a human monoclonal antibody that inhibits IL-23 and is used to treat moderate to severe plaque psoriasis, as well as psoriatic arthritis. The patent landscape for Tremfya is complex, with multiple patents held by Janssen Pharmaceuticals, the manufacturer of the drug.

When does the patent for Tremfya expire?

According to the [DrugPatentWatch.com](https://www ドラッグパテント ウォッチ.コム/) database, Janssen Pharmaceuticals holds a number of patents related to Tremfya, including US patent 9,844,404, which claims a method of treating psoriasis using guselkumab. This patent is set to expire on April 28, 2029.

However, it's worth noting that the patent landscape can change over time, and new patents may be granted or existing ones may be challenged. Additionally, patent expirations can lead to the entry of generic or biosimilar alternatives into the market, which can affect the pricing and availability of Tremfya.

Will there be generic or biosimilar versions of Tremfya?

As the patent for Tremfya begins to expire, it's likely that generic or biosimilar versions of the drug will enter the market. Janssen Pharmaceuticals has already faced challenges to its patents from other companies, including Mylan N.V.

What happens if Janssen Pharmaceuticals loses its patent challenge?

If Janssen Pharmaceuticals loses its patent challenge, it's possible that generic or biosimilar versions of Tremfya will be approved by the FDA. This could lead to increased competition in the market and potentially drive down the price of the drug.

Sources:

[1] [DrugPatentWatch.com](https://www ドラッグパテント ウォッチ.コム/)
[2] Janssen Pharmaceuticals. (2020). Tremfya (guselkumab) prescribing information.
[3] FDA. (2017). Tremfya (guselkumab) approval letter.

Note: The sources listed above are just a few examples of the many resources available on the topic of Tremfya patents.